$GBIO News

Last published 9mo ago

9mo agoGBIO XOMA XOMAO XOMAPXOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.GlobeNewswireEMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies
9mo agoGBIONodThera Appoints Geoff McDonough, M.D., as Chief Executive OfficerGlobeNewswireDr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic
9mo agoGBIO MSCLF TSX:MSCL VRTXSatellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory AffairsBusiness WireExperienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the
11mo agoGBIONodThera Appoints Geoff McDonough, M.D., as Independent Board MemberGlobeNewswireBOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today
11mo agoGBIO XOMAXOMA Royalty Enters into Agreement to Acquire Generation BioGlobeNewswire- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform for
1y agoGBIOGeneration Bio Announces Third Quarter 2025 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results Cash Position: Cash,
1y agoCMPS GBIOCompass Pathways Appoints Dr. Jeffrey Jonas to Board of DirectorsBusiness WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of
1y agoGBIOGeneration Bio Announces CEO TransitionGlobeNewswire• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., Oct.
1y agoGBIOGeneration Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial ResultsGlobeNewswire• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of LAT1 and VAV1,
1y agoGBIOGeneration Bio Announces 1-for-10 Reverse Stock SplitGlobeNewswireCAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced
1y agoGBIOGeneration Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced
1y agoGBIOGeneration Bio to Present at the 2025 Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that
1y agoGBIOGeneration Bio Reports Recent Business Highlights and First Quarter 2025 Financial ResultsGlobeNewswire- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and
1y agoGBIOGeneration Bio to Present at the Needham 24th Annual Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that
1y agoGBIOGeneration Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025
1y agoGBIOGeneration Bio to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that
1y agoGBIOTubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.Business WireTubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas'
1y agoGBIOGeneration Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune DiseasesGlobeNewswireNovel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven
2y agoGBIOGeneration Bio Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsGlobeNewswireNon-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) Cash balance of $199.8 million expected to fund operations into 2H 2027
2y agoGBIOGeneration Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual CongressGlobeNewswireNew non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid nanoparticle (ctLNP) CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO)
2y agoGBIOGeneration Bio to Present at the 2024 Cantor Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
2y agoGBIOGeneration Bio Reports Second Quarter 2024 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business
2y agoGBIOGeneration Bio to Present at the Canaccord Genuity 44th Annual Growth ConferenceGlobeNewswireCAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
2y agoGBIOGeneration Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA SummitGlobeNewswireCAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
2y agoGBIOGeneration Bio Announces Recent Business Highlights and First Quarter 2024 Financial ResultsGlobeNewswire- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP) - ASGCT poster presentations described immune-quiet DNA
2y agoGBIOGeneration Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual MeetingGlobeNewswireData presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensorsRapid enzymatic synthesis continues to improve iqDNA performance through
2y agoGBIOGeneration Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingGlobeNewswireCAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six
2y agoGBIOGeneration Bio to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
2y agoGBIOGeneration Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia - Development of breakthrough immune-quiet DNA for
2y agoGBIOGeneration Bio to Present at the 2024 TD Cowen Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
2y agoGBIOGeneration Bio to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
2y agoGBIOGeneration Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA PlatformsGlobeNewswireCompany to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA) platform for lead
3y agoGBIOGeneration Bio Reports Business Highlights and Third Quarter 2023 Financial ResultsGlobeNewswire- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system showed highly selective
3y agoGBIOGeneration Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP PlatformGlobeNewswire70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle (ctLNP) platform
3y agoGBIOGeneration Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel "Immune-Quiet" DNAGlobeNewswire– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tolerability comparable
3y agoGBIOGeneration Bio to Present at the Jefferies Cell & Genetic Medicine SummitGlobeNewswireCAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
3y agoGBIOGeneration Bio to Present at the Canaccord Genuity 43rd Annual Growth ConferenceGlobeNewswireCAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt
3y agoGBIOGeneration Bio to Present at the 2023 Jefferies Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
3y agoGBIOGeneration Bio Reports Business Highlights and First Quarter 2023 Financial ResultsGlobeNewswireCompany entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells
3y agoGBIOGeneration Bio to Present at the JMP Securities Life Sciences ConferenceGlobeNewswireCAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt
3y agoGBIOGeneration Bio to Present at the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
3y agoGBIOGeneration Bio Appoints Yalonda Howze, J.D. as Chief Legal OfficerGlobeNewswireCAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda
3y agoGBIO MRNAModerna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic MedicinesACCESS NewswireCollaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nanoparticle
3y agoGBIO MRNAModerna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic MedicinesGlobeNewswireCollaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nanoparticle (ctLNP)
3y agoGBIOGeneration Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic MedicinesGlobeNewswireCAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company
3y agoGBIOGeneration Bio to Present at the 43rd Annual Cowen Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
3y agoGBIOGeneration Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswire— Company expects to announce data for Factor VIII expression in non-human primates in 2023 — Strong cash balance of $279.1M provides expected runway into 2025 CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) --
3y agoGBIOGeneration Bio to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company
4y agoGBIOGeneration Bio Reports Business Highlights and Third Quarter 2022 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business
4y agoGBIOGeneration Bio to Present at the 2022 Jefferies Cell and Genetic Medicine SummitGlobeNewswireCAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a fireside ch